ZYDUSLIFE NEWS why is Zydus Lifesciences Ltd price falling or rising
ZYDUSLIFE NEWS reasons for why stock price of Zydus Lifesciences Ltd is falling or rising
ZYDUSLIFE Zydus Lifesciences is falling or rising technical reasons
Technical analysis forecast for Zydus Lifesciences Stock is that its in a downtrend for shortterm, and I will avoid taking a BUY or a LONG trade in this stock. Look for opportunities to sell or SHORT Zydus Lifesciences ZYDUSLIFE at this time. Stock is falling and might fall more.
It appears as if Zydus Lifesciences ZYDUSLIFE gave a large move recently.
Stock of Zydus Lifesciences (ZYDUSLIFE) is trading below an important moving average line, but it crossed this line recently, which means that it could show a small or a large recovery soon enough depending on its trend.
My analysis of Zydus Lifesciences is bearish for shortterm, but trade for tomorrow is selective. Take a sell trade only if Zydus Lifesciences stays below 895.3, but if it comes above 895.3, then a intra day buy could be more profitable.
If you take a sell trade below 895.3, then use 895.3 as stoploss and 881.2 as target. However if you take a buy trade in Zydus Lifesciences, then use 895.3 as stoploss and 907.03 as target.
ZYDUSLIFE Zydus Lifesciences is falling or rising NEWS fundamental reasons
Company Announcement Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 17, 2026, titled "Zydus and Lupin sign licensing agreement for co-marketing innovative Semaglutide Injection in India". - NEWS as on 2026-03-17
Company Announcement Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 16, 2026, titled "Sentynl Therapeutics Enters into Agreement with PRG S&T to License Molecule for Hutchinson-Gilford Progeria Syndrome". - NEWS as on 2026-03-17
Company Announcement Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 14, 2026, titled "Zydus new drug discovery, Desidustat licensed to China Medical System Holdings receives approval from NMPA of China". - NEWS as on 2026-03-16
Company Announcement Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 13, 2026, titled "Zydus receives final approval from USFDA for Cevimeline Hydrochloride Capsules 30mg". - NEWS as on 2026-03-13
Company Announcement Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 12, 2026, titled "Zydus expands companion diagnostics portfolio with the launch of AI-powered Continuous Glucose Monitor DiasensTM and GlucoLiveTM". - NEWS as on 2026-03-12
Company Announcement Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 28, 2026, titled "Zydus receives final approvals from USFDA for Ivermectin Tablets USP, 3 mg and Dapsone Tablets USP, 25 mg and 100 mg". - NEWS as on 2026-03-02
Company Announcement Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 27, 2026, titled "Zydus Lifesciences announces successful clinical development of Pembrolizumab biosimilar FYB206, marking a milestone toward USFDA filing". - NEWS as on 2026-02-27
Company Announcement Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 25, 2026, titled "Zydus plans to launch innovative Semaglutide Injection in India on Day 1 of patent expiry, expanding patient access to GLP-1 therapy". - NEWS as on 2026-02-26
Company Announcement Zydus Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication - NEWS as on 2026-02-25
Company Announcement Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 19, 2026, titled "Closure of USFDA - NEWS as on 2026-02-20
Company Announcement Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 18, 2026, titled "Zydus receives final approval from USFDA for Bosentan tablets for oral suspension, 32 mg". - NEWS as on 2026-02-19
Company Announcement Zydus Lifesciences Limited has informed the Exchange about Schedule of meet - NEWS as on 2026-02-18
Company Announcement Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 17, 2026, titled "Zydus launches PEPAIR, a first in India, affordable, drug-free, handheld device for better respiratory health". - NEWS as on 2026-02-17
Company Announcement Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 14, 2026, titled "Zydus receives final approval from USFDA for Ammonium Lactate Cream, 12%". - NEWS as on 2026-02-16
More announcements and NEWS
ZYDUSLIFE Zydus Lifesciences Ltd current price & indicator signals
Recent prices of ZYDUSLIFE Zydus Lifesciences Ltd are as follows: Daily volume is divided by 10 day averaged volume
| Date | Close | Range | Change % | Volume |
| 17 Tue Mar 2026 | 889.80 | 887.85 to 902.70 | 0.33% | 1.12 times |
| 16 Mon Mar 2026 | 886.90 | 877.10 to 911.90 | -2.1% | 1.14 times |
| 13 Fri Mar 2026 | 905.90 | 901.50 to 924.60 | -1.2% | 1.35 times |
| 12 Thu Mar 2026 | 916.90 | 909.50 to 926.60 | -0.53% | 0.73 times |
| 11 Wed Mar 2026 | 921.75 | 918.00 to 936.15 | -0.15% | 0.89 times |
| 10 Tue Mar 2026 | 923.10 | 909.00 to 927.00 | 1.57% | 0.86 times |
| 09 Mon Mar 2026 | 908.85 | 885.10 to 911.90 | -0.46% | 0.76 times |
| 06 Fri Mar 2026 | 913.05 | 905.80 to 919.50 | -0.17% | 0.72 times |
| 05 Thu Mar 2026 | 914.65 | 898.10 to 918.00 | 1.98% | 0.73 times |
| 04 Wed Mar 2026 | 896.90 | 889.00 to 903.90 | -1.1% | 2.01 times |
| 02 Mon Mar 2026 | 906.90 | 893.00 to 911.45 | -1.61% | 0.81 times |
| 27 Fri Feb 2026 | 921.70 | 916.55 to 939.90 | -1.79% | 1.64 times |
Videos related to: ZYDUSLIFE NEWS why is Zydus Lifesciences Ltd price falling or rising
Hindi Basics How To Trade In FnO Futures Options Stock Market
- NSE Screeners
- NSE Daily Screener
- NSE Weekly Screener
- NSE Monthly Screener
- Support & Resistance
- NSE Shares Near Support
- NSE Shares Near Resistance


